Get the Stockscreener App
2.195
1.57%
-0.035
Context Therapeutics Inc stock is traded at $2.195, with a volume of 29,510.
It is down -1.57% in the last 24 hours and up +14.32% over the past month.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
See More
Previous Close:
$2.23
Open:
$2.23
24h Volume:
29,510
Relative Volume:
0.13
Market Cap:
$165.25M
Revenue:
-
Net Income/Loss:
$-23.96M
P/E Ratio:
-1.8761
EPS:
-1.17
Net Cash Flow:
$-21.05M
1W Performance:
-2.01%
1M Performance:
+14.32%
6M Performance:
+18.65%
1Y Performance:
+75.60%
1-Day Range:
$2.19
$2.259
1-Week Range:
$2.125
$2.3257
52-Week Range:
$0.77
$2.75
Context Therapeutics Inc Stock (CNTX) Company Profile
Name
Context Therapeutics Inc
Sector
Industry
Phone
267-225-7416
Address
2001 MARKET STREET, PHILADELPHIA
Context Therapeutics Inc Stock (CNTX) Latest News
HR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
HR+ HER2-ve Breast Cancer Pipeline Therapeutics, Assessment, - openPR
West Pharmaceutical Services Announces Upcoming Conference Presentations - MyChesCo
Windtree Therapeutics announces $27.24 million equity sale option - Investing.com
Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance
Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 17% of holdings value - Simply Wall St
Context Therapeutics to Engage Investors at November Conferences - MyChesCo
Intensity Therapeutics grants stock options to top executives - Investing.com
Context Therapeutics Inc (NASDAQ: CNTX) Gains 14.50% In Early Trade; What Lies Ahead? - Stocks Register
Context Therapeutics to Participate in Upcoming Investor Conferences in November - GlobeNewswire
Tolerance Bio Secures $17.2 Million to Advance Immune Disease Therapies - MyChesCo
Er +/Her2 -Ve Breast Cancer Pipeline 2024: Clinical Trials - openPR
Context Therapeutics to Showcase Promising Cancer Therapy at SITC Annual Meeting - MSN
Alcura Secures MIA License to Enhance Cell and Gene Therapy Importation - MSN
Context Therapeutics Announces Poster Presentation at the - GlobeNewswire
Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting - StockTitan
LVMH shows good resilience in the current context - Yahoo Finance
Unpacking Q2 Earnings: Keysight (NYSE:KEYS) In The Context Of Other Inspection Instruments Stocks - Yahoo Finance
Unpacking Q2 Earnings: Vulcan Materials (NYSE:VMC) In The Context Of Other Building Materials Stocks - Yahoo Finance
Unpacking Q2 Earnings: Flywire (NASDAQ:FLYW) In The Context Of Other Finance and HR Software Stocks - Yahoo Finance
Genelux Co. (NASDAQ:GNLX) Shares Sold by Renaissance Technologies LLC - Defense World
Both private equity firms who control a good portion of Context Therapeutics Inc. (NASDAQ:CNTX) along with institutions must be dismayed after last week's 14% decrease - Simply Wall St
Bentley Systems Partners with Google to Bring Powerful Geospatial Context and Capabilities to Infrastructure - Yahoo Finance
Virios Therapeutics shares target raised on Wex merger news - Investing.com
What was Context Therapeutics Inc (CNTX)’s performance in the last session? - US Post News
BioAtla: Numerous Catalysts Coming In Q4 (NASDAQ:BCAB) - Seeking Alpha
BioAtla to Score Up to $133M - San Diego Business Journal
Unpacking Q2 Earnings: Topgolf Callaway (NYSE:MODG) In The Context Of Other Leisure Facilities Stocks - Yahoo Finance
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024 - Quantisnow
CNTX’s Stock Market Adventure: 75.22% YTD Growth Amidst Volatility - The InvestChronicle
Context Therapeutics To Make Nasdaq Debut Today - RTTNews
Context Therapeutics Inc (CNTX) deserves closer scrutiny - US Post News
Deal Watch: Shionogi Will Market Nxera’s Insomnia Drug In Japan - Scrip
Nantahala Capital Management LLC Purchases New Position in Context Therapeutics Inc. (NASDAQ:CNTX) - MarketBeat
Unpacking Q2 Earnings: Otis (NYSE:OTIS) In The Context Of Other General Industrial Machinery Stocks - Yahoo Finance
Ratios Reveal: Breaking Down Context Therapeutics Inc (CNTX)’s Financial Health - The Dwinnex
Driehaus Capital Management LLC Purchases Shares of 2,258,065 Context Therapeutics Inc. (NASDAQ:CNTX) - MarketBeat
Unpacking Q2 Earnings: Arlo (NYSE:ARLO) In The Context Of Other Internet of Things Stocks - Yahoo Finance
Blue Owl Capital Holdings LP Takes Position in Context Therapeutics Inc. (NASDAQ:CNTX) - MarketBeat
Century Therapeutics Announces Strategic Leadership Appointments - MyChesCo
Unpacking Q2 Earnings: Winnebago (NYSE:WGO) In The Context Of Other Automobile Manufacturers Stocks - Yahoo Finance
Q3 2024 EPS Estimates for Context Therapeutics Inc. Reduced by HC Wainwright (NASDAQ:CNTX) - MarketBeat
BioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment Development - MSN
Affinity Asset Advisors LLC Sells 233,000 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World
Affinity Asset Advisors LLC Has $3.25 Million Stock Position in Context Therapeutics Inc. (NASDAQ:CNTX) - MarketBeat
Great Point Partners LLC Makes New Investment in Context Therapeutics Inc. (NASDAQ:CNTX) - MarketBeat
Ally Bridge Group NY LLC Grows Stock Holdings in Context Therapeutics Inc. (NASDAQ:CNTX) - MarketBeat
Context Therapeutics’ (CNTX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
BioAtla out-licenses T cell therapy in $134 million deal - The Pharma Letter
BioAtla licenses cancer drug candidate to Context Therapeutics By Investing.com - Investing.com Canada
BioAtla licenses cancer drug candidate to Context Therapeutics - Investing.com
Context Therapeutics Inc Stock (CNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):